Ondine Biomedical Inc (OBI) NPV
- Add to watchlist
- Create an alert
- This stock can be held in a
8.50p
8.21p
10.70p
£36.23 million
8.50p
8.21p
5.13p
n/a
0.38p (4.62%) Previous:
0.38p
12,178
n/a
15,000
Performance
1 week 1W | 11.84% | 1 year 1Y | 2.86% |
---|---|---|---|
1 month 1M | 4.62% | 2 years 2Y | 58.54% |
3 months 3M | 51.11% | 3 years 3Y | 84.68% |
6 months 6M | 13.33% | 5 years 5Y | n/a |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 1.20 | 0.64 |
Profit before tax ($m) | (14.41) | (19.37) |
Adjusted EPS (¢): | (7.00) | (10.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Ondine Biomedical to start phase three Steriwave clinical trial
17 December 2024 12:32
-
Ondine raising £8.5m to fund US clinical trial
1 November 2024 10:47
-
Ondine Biomedical gets UAE approval for Steriwave
18 October 2024 12:04
-
Ondine commencing US Phase 3 clinical trial
17 December 2024 07:00
-
Notification of Major Holdings
25 November 2024 17:00
-
Notification of Major Holdings
22 November 2024 10:31
Annual & interim reports
Annual & interim reports are not available for this stock.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.